May, 2025
May 2025
M T W T F S S
 1234
567891011
12131415161718
19202122232425
262728293031  
Ruben Mesa: Pelabresib plus Ruxolitinib for JAKi naive Myelofibrosis
Mar 12, 2025, 10:16

Ruben Mesa: Pelabresib plus Ruxolitinib for JAKi naive Myelofibrosis

Ruben Mesa, President and Executive Director of Atrium Health Levine Cancer Institute and Atrium Health Wake Forest Baptist Comprehensive Cancer Center, shared an article by Raajit K. Rampal, et al. on LinkedIn:

“Honored to have joined many wonderful colleagues in these important PhaseIII trial data for combination Pelabresib plus Ruxolitinib for JAKi naive myelofibrosis.”

Pelabresib plus ruxolitinib for JAK inhibitor-naive myelofibrosis: a randomized phase 3 trial.

Authors: Raajit K. Rampal, et al.

Ruben Mesa: Pelabresib plus Ruxolitinib for JAKi naive Myelofibrosis